Matches in SemOpenAlex for { <https://semopenalex.org/work/W2247195055> ?p ?o ?g. }
- W2247195055 abstract "Abstract Abstract 1628 Poster Board I-654 Since the cloning of the t(12 ;21) in 1995 the prognosis of children with ETV6-RUNX1(+)ALL seems to further increase in the current era. From december 2000 to july 2008, 1461 children and adolescents aged from 1 to 20 years with B cell lineage ALL have been treated according the FRALLE protocols: one for standard-risk (SR) ALL (age 1-9 y, WBC < 50 G/L, no extra medullary involvement) F2000-A; the other one FRALLE 2000-B for high and very high risk ALL (HR) (all other pts). The two protocols mainly differ by a larger use of dexamethasone and a reduced use of anthracyclins in F2000A and the use of HDMTX and a double delayed intensification in FRALLE 2000B. ETV6-RUNX1 presence has been assessed by RT-PCR in 1392 pts (i.e. 96%) and found positive in 321 pts, i.e. 23%. Initial features include a median age of 4.2 y (1.2-15.6), a sex ratio (M/F) of 1.2, a median WBC of 10 G/L(1-293). Both peripheral blood D8 response to prednisone (PRED) and D21 marrow response to chemotherapy were evaluable in 316 pts: 94% of the pts have a rapid early response at D8 and D21. Only 3% of the pts were qualified as D8 poor PRED responders and 3% slow marrow responders at D21. The D35-42 CR rate is 100%. End of induction (EOI) minimal residual disease (MRD) using Ig-TCR methods is known in 259 out of 321 pts (81%) pts. Only 4 pts (2%) had a very high (≥10-2) EOI-MRD. Five year EFS, DFS and OS are 95±2%, 95±2%, 98±1%, respectively. The 5y EFS is 96±2% for the 252 SR pts and 90±7% for the 69 HR pts, p=0.30. The 5y EFS is significantly better for children with ETV6-RUNX1(+)ALL compared to those with ETV6-RUNX1(-) B-lineage ALL: 95±2% vs 84±2%, respectively (p=.001). Nine relapses have been reported in the bone marrow (4) the testis (4), the CNS (1) after a median time of 44 m (25-68), i.e. significantly longer than in the ETV6-RUNX1(-) cases (28m (1-92), p=.01). More testis relapses are observed in boys with ETV6-RUNX1(+)ALL (4 out 7 relapses vs 2 out of 62 in boys with ETV6-RUNX1(-) ALL). These results represent a significant progress compared to the previous protocol F 93 (191 children) both in terms of EFS and overall survival (5y EFS: 95±2% vs 78±3%, p=.001; 5 y OS: 98±1% vs 92±2%, p=.001). Conclusion an excellent prognosis of children with t(12;21)/ETV6-RUNX1 positive acute lymphoblastic leukemia is now observed in the FRALLE 2000 protocol. The question of a cautious de-escalation in this subgroup will be envisaged in the next protocol. Disclosures No relevant conflicts of interest to declare." @default.
- W2247195055 created "2016-06-24" @default.
- W2247195055 creator A5000858647 @default.
- W2247195055 creator A5005516784 @default.
- W2247195055 creator A5011984974 @default.
- W2247195055 creator A5012805294 @default.
- W2247195055 creator A5015622625 @default.
- W2247195055 creator A5018536511 @default.
- W2247195055 creator A5032184750 @default.
- W2247195055 creator A5036667713 @default.
- W2247195055 creator A5037694078 @default.
- W2247195055 creator A5038791283 @default.
- W2247195055 creator A5040756049 @default.
- W2247195055 creator A5043286121 @default.
- W2247195055 creator A5047925131 @default.
- W2247195055 creator A5053450483 @default.
- W2247195055 creator A5054047613 @default.
- W2247195055 creator A5062618437 @default.
- W2247195055 creator A5062989284 @default.
- W2247195055 creator A5071962621 @default.
- W2247195055 creator A5073306699 @default.
- W2247195055 date "2009-11-20" @default.
- W2247195055 modified "2023-09-27" @default.
- W2247195055 title "Excellent Prognosis of Children with ETV6-RUNX1 Positive (+) Acute Lymphoblastic Leukemia (ALL) in the FRALLE 2000 Protocol." @default.
- W2247195055 doi "https://doi.org/10.1182/blood.v114.22.1628.1628" @default.
- W2247195055 hasPublicationYear "2009" @default.
- W2247195055 type Work @default.
- W2247195055 sameAs 2247195055 @default.
- W2247195055 citedByCount "0" @default.
- W2247195055 crossrefType "journal-article" @default.
- W2247195055 hasAuthorship W2247195055A5000858647 @default.
- W2247195055 hasAuthorship W2247195055A5005516784 @default.
- W2247195055 hasAuthorship W2247195055A5011984974 @default.
- W2247195055 hasAuthorship W2247195055A5012805294 @default.
- W2247195055 hasAuthorship W2247195055A5015622625 @default.
- W2247195055 hasAuthorship W2247195055A5018536511 @default.
- W2247195055 hasAuthorship W2247195055A5032184750 @default.
- W2247195055 hasAuthorship W2247195055A5036667713 @default.
- W2247195055 hasAuthorship W2247195055A5037694078 @default.
- W2247195055 hasAuthorship W2247195055A5038791283 @default.
- W2247195055 hasAuthorship W2247195055A5040756049 @default.
- W2247195055 hasAuthorship W2247195055A5043286121 @default.
- W2247195055 hasAuthorship W2247195055A5047925131 @default.
- W2247195055 hasAuthorship W2247195055A5053450483 @default.
- W2247195055 hasAuthorship W2247195055A5054047613 @default.
- W2247195055 hasAuthorship W2247195055A5062618437 @default.
- W2247195055 hasAuthorship W2247195055A5062989284 @default.
- W2247195055 hasAuthorship W2247195055A5071962621 @default.
- W2247195055 hasAuthorship W2247195055A5073306699 @default.
- W2247195055 hasConcept C104317684 @default.
- W2247195055 hasConcept C126322002 @default.
- W2247195055 hasConcept C138626823 @default.
- W2247195055 hasConcept C142724271 @default.
- W2247195055 hasConcept C143998085 @default.
- W2247195055 hasConcept C187212893 @default.
- W2247195055 hasConcept C204787440 @default.
- W2247195055 hasConcept C2778461978 @default.
- W2247195055 hasConcept C2780385302 @default.
- W2247195055 hasConcept C2780833115 @default.
- W2247195055 hasConcept C2909962599 @default.
- W2247195055 hasConcept C54355233 @default.
- W2247195055 hasConcept C71924100 @default.
- W2247195055 hasConcept C86803240 @default.
- W2247195055 hasConceptScore W2247195055C104317684 @default.
- W2247195055 hasConceptScore W2247195055C126322002 @default.
- W2247195055 hasConceptScore W2247195055C138626823 @default.
- W2247195055 hasConceptScore W2247195055C142724271 @default.
- W2247195055 hasConceptScore W2247195055C143998085 @default.
- W2247195055 hasConceptScore W2247195055C187212893 @default.
- W2247195055 hasConceptScore W2247195055C204787440 @default.
- W2247195055 hasConceptScore W2247195055C2778461978 @default.
- W2247195055 hasConceptScore W2247195055C2780385302 @default.
- W2247195055 hasConceptScore W2247195055C2780833115 @default.
- W2247195055 hasConceptScore W2247195055C2909962599 @default.
- W2247195055 hasConceptScore W2247195055C54355233 @default.
- W2247195055 hasConceptScore W2247195055C71924100 @default.
- W2247195055 hasConceptScore W2247195055C86803240 @default.
- W2247195055 hasLocation W22471950551 @default.
- W2247195055 hasOpenAccess W2247195055 @default.
- W2247195055 hasPrimaryLocation W22471950551 @default.
- W2247195055 hasRelatedWork W1043776582 @default.
- W2247195055 hasRelatedWork W1107239912 @default.
- W2247195055 hasRelatedWork W1963243098 @default.
- W2247195055 hasRelatedWork W1968622258 @default.
- W2247195055 hasRelatedWork W2010518012 @default.
- W2247195055 hasRelatedWork W2073520867 @default.
- W2247195055 hasRelatedWork W2086392598 @default.
- W2247195055 hasRelatedWork W2089522240 @default.
- W2247195055 hasRelatedWork W2107662285 @default.
- W2247195055 hasRelatedWork W2137624458 @default.
- W2247195055 hasRelatedWork W2138919007 @default.
- W2247195055 hasRelatedWork W2163280869 @default.
- W2247195055 hasRelatedWork W2603007887 @default.
- W2247195055 hasRelatedWork W2793008176 @default.
- W2247195055 hasRelatedWork W2807805118 @default.
- W2247195055 hasRelatedWork W2891521862 @default.
- W2247195055 hasRelatedWork W2980420491 @default.
- W2247195055 hasRelatedWork W3010136928 @default.
- W2247195055 hasRelatedWork W3142089820 @default.
- W2247195055 hasRelatedWork W3212093211 @default.